Table 1 Baseline clinical and viro-immunological characteristics of 97 HIV-infected pregnant women naive for any antiretroviral drug
Characteristics | All pregnant women |
|---|---|
n° 97 | |
Age, years, mean ± SD; median, (IQR) | 29,±5; 28 (25–32) |
Gestational age at enrolment, week, mean ± SD | 20 ± 5 |
Height at screening, cm, median (IQR) | 155 (153–159) |
Race/ethnicity, n. (%) | |
Black African | 97 (100) |
Education, n. (%) | |
Primary school | 66 (68.0) |
Secondary school | 17 (17.5) |
Other or unknown | 14 (14.5) |
Number of pregnancies, mean ± SD | 3 ±1 |
Number of deliveries, mean ± SD | 2 ±1 |
Number of children, mean +/-SD | 1 ±1 |
HIV risk factor, n. (%) | |
Unprotected heterosexual relationship | 97 (100) |
WHO stage, n. (%) | |
1 | 53 (54.6) |
2 | 27 (27.8) |
3 | 15 (15.5) |
4 | 2 (2.1) |
Days since HIV diagnosis, median (IQR) | 136 (94–164) |
MedianCD4+ cells at enrolment /μL (IQR) | 392 (260–528) |
Median log10 HIV RNA copies/mL (IQR) | 4.80 (4.03–9.28) |
Eligible for HAART, n (%) | 19 (19.6%) |
Positive VDRL assay, n (%) | 3 (3.1) |